Citigroup Downgrades Aerie Pharmaceuticals to Neutral

Citigroup analyst Yigal Nochomovitz downgrades Aerie Pharmaceuticals (NASDAQ:AERI) from Buy to Neutral.

byBenzinga Newsdesk

August 29, 2022

1 minute read

Citigroup analyst Yigal Nochomovitz downgrades Aerie Pharmaceuticals (NASDAQ:AERI) from Buy to Neutral.

EF Hutton Initiates Coverage On Superior Drilling Prods with Buy Rating, Announces Price Target of $2

By Benzinga Newsdesk

June 9, 7:09 AM

EF Hutton analyst Ben Piggott initiates coverage on Superior Drilling Prods (AMEX:SDPI) with a Buy rating and announces Price Target of $2.

SDPI

3D Systems, CollPlant Report Co-Development Deal To Deliver Bioprinted Solutions For Improved Breast Reconstruction Treatments, No Terms Disclosed

By Benzinga Newsdesk

June 22, 8:33 AM

Today, 3D Systems (NYSE:DDD) and CollPlant Biotechnologies (NASDAQ:CLGN) announced they have signed a co-development agreement for a 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction

CLGN

Selecta Biosciences Posts Encouraging Data For ImmTOR Platform

By Vandana Singh

November 8, 1:39 PM

Selecta Biosciences Inc (NASDAQ:SELB) announced top-line results from the Phase 1 study evaluating the ImmTOR platform to mitigate the formation of…

SELB

Recap: Darden Restaurants Q2 Earnings

By Benzinga Insights

December 17, 8:11 AM

Darden Restaurants (NYSE:DRI) reported its Q2 earnings results on Friday, December 17, 2021 at 07:00 AM. Here's what investors need to know about the announcement.

DRI

Citigroup Downgrades Aerie Pharmaceuticals to Neutral

Related Posts

EF Hutton Initiates Coverage On Superior Drilling Prods with Buy Rating, Announces Price Target of $2

3D Systems, CollPlant Report Co-Development Deal To Deliver Bioprinted Solutions For Improved Breast Reconstruction Treatments, No Terms Disclosed

Selecta Biosciences Posts Encouraging Data For ImmTOR Platform

Recap: Darden Restaurants Q2 Earnings